

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 11748-006-999	<b>APPLICATION NO.</b> 10/516,759
	<b>APPLICANT</b> Mingdong Zhou	
	<b>FILING DATE</b> March 3, 2006	<b>ART UNIT</b> 1642

### U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

### FOREIGN PATENT DOCUMENTS

*Examiner Initials	Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B13	WO 98/17797 A1	Genentech, Inc.		

### NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C45 BANDYOPADHYAY et al., "Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells," J Biol Chem., 1998, 273: 1568-1573.	
	C46 FARESS et al., "Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2," J Appl Physiol., 2007 103: 2077-2083.	
	C47 HUDZIAK et al., "p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor," 1989, Mol Cell Biol, 9: 1165-1172.	
	C48 INTERNATIONAL PRELIMINARY EXAMINATION REPORT of PCT/AU00/00671.	
	C49 LEVY et al., "Biological and clinical implications of lymphocyte hybridomas: tumor therapy with monoclonal antibodies," Annu Rev Med., 1983, 34: 107-116.	
	C50 LEWIS et al., "Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies," Cancer Immunol Immunother., 1993, 37: 255-263.	
	C51 LEWIS et al., "Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness," Cancer Res., 1996, 56: 1457-1465.	
	C52 SCHROFF et al., "T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients," J Immunol., 1984, 133: 1641-1648.	
	C53 STOICA et al., "Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway," Oncogene, 2003, 22: 7998-8011.	
	C54 VADLAMUDI et al., "Regulation of cyclooxygenase-2 pathway by HER2 receptor," Oncogene, 1999, 18: 305-314.	
	C55 WANG et al., "Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology," Proc Natl Acad Sci U S A., 1998, 95: 14821-14826	
	C56 XU et al., "Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185," Int J Cancer, 1993, 53: 401-408.	

**EXAMINER**  
 SHI-77649v1

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 11748-006-999	<b>APPLICATION NO.</b> 10/516,759
	<b>APPLICANT</b> Mingdong Zhou	
	<b>FILING DATE</b> March 3, 2006	<b>ART UNIT</b> 1642

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
C57	YE et al., "Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225," Oncogene, 1999, 18: 731-738			

<b>EXAMINER</b> SHI-77649v1	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	